Articles

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)

Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need   Cambridge, UK. Monday 6th February 2017 – Exonate, an early stage biotechnology company has been awarded a £4.9m Seeding Drug Discovery award by the Wellcome Trust to continue development of an eye – drop treatment for wet age–related macular degeneration.  …

Details

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)

Exonate closes successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD) New and existing investors participated in the round Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Wednesday [30th] November 2016 – Exonate, an early stage biotechnology company, today announced they…

Details